Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
These usually subside as the body adjusts to the medication
CAGR 11.79% value / 17.98% volume second fastest-growing segment Largest application: Diabetes & Obesity (GLP-1 adoption for obesity unlocking massive new patient populations via Wegovy and Zepbound) North America: 49.8% market share (2026)
GLP-1 agonists like semaglutide and tirzepatide, used for weight loss
DMSO, ethanol, methanol, or acetonitrile are commonly evaluated for small-scale reference preparations, while aqueous buffers may require co-solvent optimization
PMID: 24303868 Brescoll J, Daveluy S
US$ 20.88
US$ 22.34
US$ 23.72
US$ 26.16
US$ 20.62
US$ 28.66
US$ 28.63
